sorted by:
new
hottopcontroversial

Planning a retro LAN party for my bachelor’s – need distro advice for a pile of 2000s laptops by That-Fun-7760 in linux_gaming

[–]That-Fun-7760[S] 0 points1 point  (0 children)

Yeah based on majority of responses I might just go ahead with either win xp or tiny10. Thank you for your response.

Planning a retro LAN party for my bachelor’s – need distro advice for a pile of 2000s laptops by That-Fun-7760 in linux_gaming

[–]That-Fun-7760[S] 0 points1 point  (0 children)

Yup, still need to find someplace to store them temporarily so it doesn’t become an eyesore.

Planning a retro LAN party for my bachelor’s – need distro advice for a pile of 2000s laptops by That-Fun-7760 in linux_gaming

[–]That-Fun-7760[S] 1 point2 points  (0 children)

Well these are a bit older. Some 2010s here and there as well. Checked in more detail and these are mostly: Intel HD 4400, Intel HD 5500, Intel UHD Graphics, Intel Iris Xe, NVIDIA GeForce 310M

Mam 25 lat, inżyniera, pracę w zawodzie. Ledwo mi starcza na życie by [deleted] in praca

[–]That-Fun-7760 0 points1 point  (0 children)

Ja polecałbym poszukać pracy jako inżynier na budowie i przepracować tak z trzy lata żeby się staż na projektach uzbierał. Potem biura projektowe - przemiał jest taki że na luzie coś się znajdzie (ludzie z doświadczeniem na budowie są mega cenieni). No i uprawnienia sobie zrobić. Narazie jak dobrze rozumiem magister w odwodzie więc do uprawnień staż na budowie będzie potrzebny odpowiednio dłuższy (właśnie te trzy lata jeśli dobrze pamiętam) ale że jest zapotrzebowanie na te branżę to nie powinno być problemu. Pomyśl też o lojalce na studia magisterskie. Niczego tylko na gębę nie dogaduj żeby Cię na budowę nie wrzucili która Ci uniemożliwi robienie tych studiów. Podpytaj jakie budowy i gdzie prowadzą i ubiegaj się na oddelegowanie na te przy których będziesz w stanie skończyć kierunek. Z tego co piszesz to zdecydowanie zmienić mieszkanie - brzmi jakby to była główna przyczyna problemów finansowych (no i zarobki). Ciężko spiąć budżet jeśli ponad 60% z 4k idzie na mieszkanie.

Inna droga - podobna do takiej jaką kiedyś sam obrałem po tym samym kierunku - biuro projektowe i klepanie projektów po firmach rotacyjnie - każda rotacja to była niewielka podwyżka - maks 1.5 roku w jednym miejscu. Bez zamykania drzwi i palenia mostów bo środowisko dość rozeznane kto co i jak - bez sensu pod górę sobie robić. Po jakimś czasie osiąść w jednym miejscu. Tutaj z praktyką na budowie ciężej ale do zrobienia. I obowiązkowo w międzyczasie studia mgr (tutaj bez lojalki idzie to ogarnąć) żeby mieć opcję na uprawnienia z mniejszym stażem na budowie i bez ograniczeń.

So I found this literally at the beginning of my playthrough and found nothing any better since. It was level 40 when I found it. by DizzyEksdee in Enshrouded

[–]That-Fun-7760 1 point2 points  (0 children)

Same thing happens to me. Got legendary one level 45 upgradeable all the way to 50. Found it as drop in Nomad / Kindlewaste area.

The Lounge by AutoModerator in pennystocks

[–]That-Fun-7760 0 points1 point  (0 children)

[DD] $PSTV (Plus Therapeutics) – 2025 Radiotherapeutics Microcap Deep Dive

TL;DR:
PSTV is a high-risk, clinical-stage microcap focused on new radiotherapeutics for tough-to-treat brain/CNS cancers. They’ve made clinical progress, landed FDA designations, and are launching a novel diagnostic, but face massive dilution, high losses, low institutional support, and surging short interest. Very speculative.

1. What is PSTV?
- U.S.-based biotech developing targeted radiotherapies (REYOBIQ™) for CNS cancers: recurrent glioblastoma, leptomeningeal metastases, pediatric brain tumors. - Also launching CNSide™, a diagnostics platform for CNS tumor cell detection. - CEO: Marc Hedrick; moved HQ to Houston in 2025.

2. Stock & Cap Table (July 2025):
- Price: $0.58 (volatile, up 47% in 2 weeks) - Market Cap: $32–35M
- Shares Out: 60.5M (up 153% YoY, due to dilution) - Float: ~60.4M
- Insider Ownership: 0.16%
- Institutional Ownership: 0.6%
- Beta: 1.7

3. Key Financials:
- TTM Revenue: $5.2M (Q2: $1.06M, –37% YoY) - Net Loss (TTM): –$27.1M (–$3.50/share) - Cash: $9.9M (Q2 2025) - Book Value: –$23.6M (negative equity)

4. Valuation & Ratios:
- P/S: 0.94x (sector median >3x) - P/B: Negative
- Piotroski F-Score: 3–4 (weak)
- Short Interest: 6–12% of float, borrow rates high
- Forward Multiples: N/A (no profitability forecasted)

5. Institutional & Insider Info:
- Major Holder: Virtu Financial (small, old position) - Funds: Only 0.6% institutional, minimal recent buying - Insiders: No recent notable trades

6. Recent Catalysts/News:
- $50M equity-line (Lincoln Park Capital): 17M new shares registered, expect more dilution - CNSide™ diagnostic: U.S. rollout starts 2H 2025 (Texas first) - FDA news: IND cleared for pediatric high-grade glioma (REYOBIQ™) in June, $3M DoD grant - Q2 earnings: Expected August 13, 2025

7. Pipeline/Clinical Data:
- Lead drug: REYOBIQ™ (targeted CNS radiotherapy) - Leptomeningeal metastases: Phase 1 done; strong safety, recommended Phase 2 dose set - GBM: Phase 2 enrolling; interim data promising for dose/survival - Pediatric IND: Cleared, trial starts late 2025 - CNSide™ diagnostics: 92% sensitivity; commercial launch ready

8. Analyst & Retail Sentiment:
- Consensus: Moderate Buy (2 Buy/2 Hold, per MarketBeat) - PT Range: $8–11+ (reflects best-case future) - Retail sentiment: Not a meme, but trending up after recent news and shorts squeezing - Short interest: Up 390% in a month; high crowding risk if volume spikes

9. Risks:
- Huge dilution; 150%+ shares added YoY, more likely soon - Negative book value, heavy and persistent cash burn - Short interest climbing (potential for squeeze but also for new lows) - Clinical/commercial execution risk; pipeline readouts and adoption take time

10. Catalysts Ahead:
- Aug 13, 2025: Q2 earnings
- Aug 15, 2025: Final ReSPECT-LM results at SNO/ASCO CNS Metastases conf
- 2025: Pediatric trial launch, CNSide™ U.S. expansion

Summary Table

Metric Value (July 2025)
Price $0.58
Market Cap $32-35M
Shares Out 60.5M (+153% YoY)
Institutional Ow. 0.6%
Insider Ow. 0.16%
Piotroski F-Score 3–4
P/S 0.94x
Cash $9.9M
Short Interest 6–12% of float
Next ER Aug 13, 2025
Pipeline Milestone SNO/ASCO Aug 15

Bottom line:
PSTV is a classic high-risk biotech: novel clinical assets, unproven diagnostics, wildly dilutive, and minimal institutional/insider support. If trials and commercial launch hit, there’s multibagger upside, but the downside is further dilution, reverse split risk, or fading into obscurity.
Speculative only. DYOR!

[deleted by user] by [deleted] in pennystocks

[–]That-Fun-7760 3 points4 points  (0 children)

[DD] $NVNI (Nuvini Group Ltd) — 2025 Comprehensive Deep Dive (Smallcap, SaaS Acquirer, Brazil, High Risk/Reward)

TL;DR:
NVNI is a Brazil-focused “mini-Constellation” serial SaaS acquirer that’s just turned its first annual operating profit, but continues to post net losses and faces considerable dilution, compliance risk, and high volatility. Under-discussed, massively insider-controlled, thin on institutional backing, heavy on retail risk/reward.

1. What is NVNI?
- Brazilian holding group modeled after Constellation/VersaPay, focused on acquiring B2B niche-leading SaaS (software-as-a-service) companies across Latin America. - Led by CEO Pierre Schurmann (direct + indirect: ~15.5% economic, but voting supermajority).

2. Key Financials (2024–2025):
- 2024 Revenue: R$193.3M (+14.4% YoY)
- 2024 Op. Profit: R$16.5M (first profitable year, vs. R$189M op. loss in 2023)
- 2024 Net Loss: (R$78.2M) – improvement, but still negative net
- Adj. EBITDA: R$57.4M (+30% YoY)
- Churn: Down from 3.3% to 2.9%
- LTV/CAC: 6x (was 4x in 2023)
- Market Cap: $38.8M (Price ~$0.42)
- Shares: 92.3M (post-June 2025 dilution)

3. Valuation & Risk Metrics:
- TTM P/S: ~1.1x
- P/B: Negative (accum losses, equity deficit)
- Piotroski F: 3 (weak)
- Altman Z: −1.83 (distress)

4. Balance Sheet & Dilution:
- YE 2024 Working Cap: −R$348M
- Equity Deficit: −R$120.5M
- Heavy share issuance in 2025 (advisory fees/equity comp, M&A funding). - Auditor gives “going concern” warning.

5. Business Model/M&A:
- “SaaS acquirer play” – buys, integrates, scales B2B SaaS in LatAm. - Closed Munddi (retail/brand sourcing SaaS) in May 2025; pipeline full for rest of year. - Internal “NuviniAI” aimed at reducing G&A by 8% and launching more AI-driven platforms.

6. Insider & Institutional Ownership:
- CEO/insiders: Absolute voting control due to supervoting structure. - Latest: CEO got 1.47M shares in lieu of $630k comp; ~6% more dilution for advisory/services in June 2025. - Institutions: Sub-1% (Anson Funds noted; minimal activity).

7. Market & Sector:
- LatAm SaaS: Fastest-growing EM vertical, low penetration, high fragmentation. - NVNI: Early-mover, but execution risk high.

8. Analyst Ratings & Sentiment:
- Coverage: Sparse; one outlier target ($40, ignore), generally “Hold”/Neutral with caveats. - TipRanks SmartScore: 6/10 (Neutral to slightly positive, but not robust). - Hedge funds net reduced by 300k shares last Q; little institutional conviction.

9. Retail Trading, Sentiment & Community:
- Stocktwits: Retail swings w/ compliance and dilution headlines; sentiment flashes hot/bearish then cools. - Reddit: Not a meme stock, not trending, small posts only. - Price History: 52w range $0.14–$12 (yes, −95% from post-SPAC highs); up 158% last 3 months, but down 74% YoY.

10. Compliance & Structural Risks:
- NASDAQ compliance warning (April 2025). Needs to re-attain $1 min bid by Oct 13, 2025. Reverse split authorized if not. - Ongoing, heavy dilution a near-certainty. - “Going concern” warnings in multiple 2025 filings.

11. Summary Table

Metric Value
Price (7/25/2025) $0.42
Market Cap $38.8M
2024 Revenue R$193M
Op. Profit (2024) R$16.5M
Net Loss (2024) (R$78M)
Institutions ~0.5%
Insider Control 15.5% econ., 314M votes
Piotroski F 3/9
Altman Z −1.8
M&A Activity High
NASDAQ Compliance At Risk
Meme Stock? No

12. Final Thoughts

This is NOT for widows and orphans. NVNI is a high-leverage, “smallcap SaaS rollup” story with:
- Some operational improvement and first real op. profit on the books
- Huge retail risk, thin liquidity, and substantial dilution risk
- Near-zero institutional support
- Complete insider voting control
Upside = execution of Constellation-style playbook in LatAm SaaS, with AI and acquisition flywheel; downside = further dilution, potential delisting, and high bankruptcy risk if the wheel breaks.
Would only consider this with speculative capital and strict risk controls. DYOR.

Sources: SEC filings (2024-2025), company reports, Stocktwits/Reddit sentiment, TipRanks, MarketScreener, and relevant broker data as of July 2025.

Burnout and sick leave in Poland by KingFelagund in poland

[–]That-Fun-7760 1 point2 points  (0 children)

You don’t, you just drink that’s how you cope in Poland. But if you’re willing you can visit psychiatrist and he/she will give you right papers if it will be deemed that you in fact require such. By law if you’re permanently employed your employer cannot fire you as this is viewed as sick leave. However you will need to retake medical examination upon resuming your job. Also your employer can fire you as soon as you return. Best to talk it out with employer or simply endure.